Specify a stock or a cryptocurrency in the search bar to get a summary
ChemoMetec A/S
CHEMMChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer. In addition, the company provides consumables comprising cassettes, reagents, lysis, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans and training. Further, it develops as well as develops XcytoMatic 30 cell counter. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark. Address: Gydevang 43, Allerød, Denmark, 3450
Analytics
WallStreet Target Price
3 102.54 DKKP/E ratio
61.707Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CHEMM
Dividend Analytics CHEMM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
263 %Dividend History CHEMM
Stock Valuation CHEMM
Financials CHEMM
Results | 2019 | Dynamics |